CARSGEN-B (02171) Completes First Patient Infusion in China Phase I Registration Trial of CT1190B

Stock News

Sep 29

According to an announcement by CARSGEN-B (02171), CT1190B, a universal CAR-T cell product targeting CD19/CD20, has completed the first patient infusion in its Phase I registration clinical trial conducted in China.

The therapy is intended for the treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) who have failed at least two lines of standard treatment.

The results of the IIT study for CT1190B have already been presented as a poster at the 2026 European Hematology Association (EHA) Annual Meeting.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/news/1146102396"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1146102396\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1146102396?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-29 08:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146102396","market":"us","top_or_hot":-1,"title":"CARSGEN-B (02171) Completes First Patient Infusion in China Phase I Registration Trial of CT1190B","media":"Stock News","content":"<p>According to an announcement by <b>CARSGEN-B</b> (<b>02171</b>), CT1190B, a universal CAR-T cell product targeting CD19/CD20, has completed the first patient infusion in its Phase I registration clinical trial conducted in China.<br><br>The therapy is intended for the treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) who have failed at least two lines of standard treatment.<br><br>The results of the IIT study for CT1190B have already been presented as a poster at the 2026 European Hematology Association (EHA) Annual Meeting.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CARSGEN-B (02171) Completes First Patient Infusion in China Phase I Registration Trial of CT1190B</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCARSGEN-B (02171) Completes First Patient Infusion in China Phase I Registration Trial of CT1190B\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-29 08:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to an announcement by <b>CARSGEN-B</b> (<b>02171</b>), CT1190B, a universal CAR-T cell product targeting CD19/CD20, has completed the first patient infusion in its Phase I registration clinical trial conducted in China.<br><br>The therapy is intended for the treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) who have failed at least two lines of standard treatment.<br><br>The results of the IIT study for CT1190B have already been presented as a poster at the 2026 European Hematology Association (EHA) Annual Meeting.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDTX","symbol_name":"Corgi MediaTek 2x Daily ETF","start_time":0,"source_url":"","article_id":"1146102396","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146102396","pubTimestamp":1790640613,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to an announcement by CARSGEN-B (02171), CT1190B, a universal CAR-T cell product targeting CD19/CD20, has completed the first patient infusion in its Phase I registration clinical trial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDTX":"Corgi MediaTek 2x Daily ETF","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","BK1161":"生物科技","BK1587":"次新股","BK1574":"生物医药B类股","BK1585":"昨日强势股","02171":"科济药业-B","PSYK":"PSYK ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","BMED":"iShares Health Innovation Active ETF"},"translate_title":"CARSGEN-B(02171)完成CT1190B中国I期注册试验首例患者输注","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBBQ":1,"MDTX":1,"BMED":1,"02171":1,"IBBJ":1,"PSYK":1},"content_text":"According to an announcement by CARSGEN-B (02171), CT1190B, a universal CAR-T cell product targeting CD19/CD20, has completed the first patient infusion in its Phase I registration clinical trial conducted in China.The therapy is intended for the treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) who have failed at least two lines of standard treatment.The results of the IIT study for CT1190B have already been presented as a poster at the 2026 European Hematology Association (EHA) Annual Meeting.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}